

# Josep M Llibre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5821605/publications.pdf>

Version: 2024-02-01

72  
papers

1,912  
citations

361413

20  
h-index

265206

42  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Practical measures for SARS-CoV-2 infection prevention – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 21.	9.1	0
2	SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression. <i>Microorganisms</i> , 2022, 10, 143.	3.6	11
3	Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort. <i>HIV Medicine</i> , 2022, 23, 825-836.	2.2	5
4	Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1738-1740.	3.0	9
5	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
6	Game-changing study of second-line HIV treatment. <i>Lancet HIV</i> , the, 2022, 9, e368-e369.	4.7	0
7	Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of <i>Clostridioides difficile</i> Infection. <i>Microorganisms</i> , 2022, 10, 1075.	3.6	1
8	Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2265-2273.	3.0	13
9	Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 938-940.	4.0	1
10	Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1964-e1972.	5.8	167
11	Redefining therapeutic success in HIV patients: an expert view. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2501-2518.	3.0	15
12	Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7129.	2.6	7
13	Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study. <i>Annals of Internal Medicine</i> , 2021, 174, 1487-1488.	3.9	23
14	Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1365-1372.	9.1	73
15	Reassessing oral lead-in for injectable long-acting HIV therapy. <i>Lancet HIV</i> , the, 2021, 8, e660-e661.	4.7	2
16	The potential role of bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. <i>HIV Medicine</i> , 2020, 21, 3-16.	2.2	17
17	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. <i>HIV Medicine</i> , 2019, 20, 237-247.	2.2	32
18	Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 2089.	2.4	20

#	ARTICLE	IF	CITATIONS
19	Costâ€effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2018, 36, 16-20.	0.3	0
20	Costâ€effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 16-20.	0.5	6
21	Nucleoside reverse transcriptase inhibitorâ€reducing strategies in HIV treatment: assessing the evidence. <i>HIV Medicine</i> , 2018, 19, 18-32.	2.2	31
22	Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors. <i>Aids</i> , 2018, 32, 121-125.	2.2	21
23	Desarrollo de darunavir en todo el espectro de la infecciÃ³n por el VIH. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 3-9.	0.5	2
24	Cuidados clÃnicos del paciente con VIH. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 40-44.	0.5	5
25	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 29-32.	1.1	5
26	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 493-498.	0.5	3
27	Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 442-446.	2.5	31
28	Time to get serious with HIV-1 resistance in sub-Saharan Africa. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 241-243.	9.1	6
29	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2017, 35, 491-496.	0.3	0
30	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression. <i>Medicine (United States)</i> , 2016, 95, e5020.	1.0	2
31	Abacavir and cardiovascular disease: A critical look at the data. <i>Antiviral Research</i> , 2016, 132, 116-121.	4.1	26
32	Host and disease factors are associated with cognitive function in European <scp>HIV</scp>â€infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
33	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1346-1351.	3.0	3
34	Backbones versus core agents in initial ART regimens: one game, two players. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 856-861.	3.0	15
35	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2016, 34, 361-371.	0.5	10
36	EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment. <i>PLoS ONE</i> , 2016, 11, e0149007.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1124-1129.	3.0	13
38	Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. <i>HIV Medicine</i> , 2015, 16, 628-634.	2.2	14
39	Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4287.	4.3	2
40	Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. <i>Aids</i> , 2015, 29, 373-383.	2.2	87
41	The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 893-897.	1.1	4
42	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	4.1	16
43	Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 156-165.	0.5	12
44	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	5.8	100
45	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
46	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. <i>PLoS ONE</i> , 2015, 10, e0128131.	2.5	4
47	Genetic barrier to resistance for dolutegravir. <i>AIDS Reviews</i> , 2015, 17, 56-64.	1.0	65
48	Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance. <i>HIV Medicine</i> , 2014, 15, 193-195.	2.2	4
49	Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 598-602.	0.5	9
50	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. <i>Aids</i> , 2014, 28, 325-334.	2.2	62
51	<i>Pneumocystis jirovecii</i> pneumonia in HIV-1-infected patients in the late-HAART era in developed countries. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 635-644.	1.5	20
52	From TMC114 to darunavir: five years of data on efficacy. <i>AIDS Reviews</i> , 2013, 15, 112-21.	1.0	14
53	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. <i>Antiviral Therapy</i> , 2012, 17, 355-364.	1.0	108
54	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1462-1469.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort. <i>Aids</i> , 2012, 26, 2117-2118.	2.2	2
56	Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. <i>AIDS Reviews</i> , 2012, 14, 168-78.	1.0	40
57	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	1.0	35
58	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011, 25, 1683-1690.	2.2	43
59	Baseline CD4 <sup>+</sup> T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. <i>Antiviral Therapy</i> , 2011, 16, 395-404.	1.0	19
60	Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 713-717.	1.1	7
61	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 358-362.	3.0	20
62	The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e46-e48.	2.1	1
63	Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir. <i>Antiviral Therapy</i> , 2010, 15, 959-961.	1.0	2
64	Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1-Infected Patients with Virologic Failure. <i>Clinical Infectious Diseases</i> , 2010, 50, 872-881.	5.8	51
65	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	1.0	42
66	The Changing Face of HIV/AIDS in Treated Patients. <i>Current HIV Research</i> , 2009, 7, 365-377.	0.5	28
67	HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. <i>AIDS Reviews</i> , 2009, 11, 39-51.	1.0	16
68	First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better. <i>AIDS Reviews</i> , 2009, 11, 215-22.	1.0	21
69	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. <i>HIV Medicine</i> , 2008, 9, 508-513.	2.2	8
70	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 206-209.	3.0	8
71	Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 139-147.	2.1	127
72	Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 2003, 349, 1036-1046.	27.0	303